Calliditas Therapeutics AB American Depositary Shares
CALT
CALT was delisted on the 20th of September, 2024.
14 hedge funds and large institutions have $21M invested in Calliditas Therapeutics AB American Depositary Shares in 2023 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 6 closing their positions.
38% more capital invested
Capital invested by funds: $15.2M → $21M (+$5.83M)
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
30% more call options, than puts
Call options by funds: $498K | Put options by funds: $383K
22% less funds holding
Funds holding: 18 → 14 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$379K |
| 2 |
IIM
Ironwood Investment Management
Boston,
Massachusetts
|
+$29.7K |
| 3 |
Group One Trading
Chicago,
Illinois
|
+$14.1K |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$9.99K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$1.76K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Optiver Holding
Amsterdam,
Netherlands
|
-$122K |
| 2 |
HSA
HBK Sorce Advisory
Erie,
Pennsylvania
|
-$104K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$15.2K |
| 4 |
IA
IFP Advisors
Tampa,
Florida
|
-$7K |
| 5 |
JP Morgan Chase
New York
|
-$5K |
CALT Hedge Fund Activity: Q1 2023 in Review
14 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Calliditas Therapeutics AB American Depositary Shares (CALT) for Q1 2023, worth a combined $21M — up 38% from $15.2M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of CALT and 2 opened new positions — a net loss of 4 holders — while 3 trimmed existing stakes and 4 added.
The largest buyer was Deutsche Bank, adding an estimated $379K. The largest seller was Optiver Holding, cutting an estimated $122K.
- 14 institutional investors held Calliditas Therapeutics AB American Depositary Shares (CALT) as of Q1 2023, down from 18 in Q4 2022.
- Funds reported $21M of Calliditas Therapeutics AB American Depositary Shares stock for Q1 2023, up 38% quarter-over-quarter.
- 2 funds opened new Calliditas Therapeutics AB American Depositary Shares positions in Q1 2023 and 6 closed out, a net change of -4 holders.
- The largest Calliditas Therapeutics AB American Depositary Shares buyer in Q1 2023 was Deutsche Bank, an estimated $379K added.
- The largest Calliditas Therapeutics AB American Depositary Shares seller in Q1 2023 was Optiver Holding, an estimated $122K sold.
Based on aggregated 13F filings for Q1 2023.